Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
Y Asano, N Yamamoto, S Demura, K Hayashi… - Lung Cancer, 2024 - Elsevier
Background The concomitant use of denosumab and immune checkpoint inhibitor (ICI)
treatment may have synergistic effects and enhance antitumor activity; however, this has not …
treatment may have synergistic effects and enhance antitumor activity; however, this has not …
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
Y Asano, N Yamamoto, S Demura, K Hayashi… - Lung … - lungcancerjournal.info
Background The concomitant use of denosumab and immune checkpoint inhibitor (ICI)
treatment may have synergistic effects and enhance antitumor activity; however, this has not …
treatment may have synergistic effects and enhance antitumor activity; however, this has not …